Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.
Harbour BioMed is building its proprietary pipeline through internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.
Harbour BioMed was founded in 2016 by Jingsong Wang. The company is headquartered in Cambridge, Massachusetts, with offices in Rotterdam, Netherlands and Shanghai, China.
Harbour BioMed's discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms（Harbour Mice®）for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies.
Harbour BioMed is backed by GIC, SK Holdings, OrbiMed, Legend Capital, Hudson Bay Capital, AdvanTech, Greater Bay Area Fund, Efung Capital and others. The company completed its Series C of $102.8M on Jul 09, 2020. The round follows a $75M Series B+ financing in March 2020. This new investment brings Harbour BioMed's total funding to $312.8M to date.